Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Al Tamimi, Dalal M ^a   Shawarby, Mohamed A ^a   Ahmed, Ayesha ^a   Hassan, Ammar K ^a   AlOdaini, Amal A ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; EGFR PROTEIN, HUMAN; HER2 PROTEIN, HUMAN; KRT5 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER MORPHOLOGY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PREVALENCE; PROTEIN EXPRESSION; SAUDI ARABIA; TUMOR CLASSIFICATION; ARAB; BREAST TUMOR; CANCER STAGING; CELL PROLIFERATION; CHEMISTRY; ETHNOLOGY; FEMALE; GENETICS; HEALTH SURVEY; IN SITU HYBRIDIZATION; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; ARABS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KERATIN-5; KERATIN-6; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SAUDI ARABIA; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952441811     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-223     Document Type: Article

References (58)

1. Tarone RE. Breast cancer trends among young women in the United States. Epidemiology 2006, 17(5):588-590. 10.1097/01.ede.0000229195.98786.ee, 16804474.
2. Al-Kuraya K, Schramel P, Skeik, Amr S, Torhorst J, Tapia C, Novotny H, Spichtin H, Maurer R, Mirlacher M, Simon R, Sauter G. Predominance of high grade pathway in breast cancer development of middle east. Modern Pathology 2005, 18:891-897. 10.1038/modpathol.3800408, 15803183.
3. Registry NC. Cancer Incidence Report Saudi Arabia 2002. Riyadh 2007,
4. Ibrahim EM, al-Mulhim FA, al-Amri A, al-Muhanna FA, Ezzat AA, Stuart RK, Ajarim D. Breast cancer in the Eastern province of Saudi Arabia. Med Oncol 1998, 15(4):241-247. 10.1007/BF02787207, 9951687.
5. Ezzat AA, Ibrahim EM, Raja MA, Al-Sobhi S, Rostom A, Stuart RK. Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med Oncology 1999, 16(2):95-103.
6. Pusztai L, Cristofanilli M, Paik S. New generation of molecular prognostic and predictive tests for breast cancer. Semin Oncol 2007, 34(2 Suppl 3):S10-6. 10.1053/j.seminoncol.2007.03.015, 17512431.
7. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist 2006, 11(8):868-877. 10.1634/theoncologist.11-8-868, 16951390.
8. Wood WCMH, Solin LJ, Olopade OI. Malignant tumors of the breast 2005, Philadelphia: Lippincott Wiliams & Wilkins, 7.
9. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1865-1878.
10. Perou CM, Sorlie T, Eisen MB, Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
11. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003, 9:2406-2415.
12. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D. Repeated observation of breast tumor sub types in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
13. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398. 10.1073/pnas.1732912100, 193572, 12917485.
14. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, Rijn M, Perou CM. Immunohistochemical and clinicalcharacterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
15. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO. Highthroughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005, 116:340-350. 10.1002/ijc.21004, 15818618.
16. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005, 65:767-779.
17. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
18. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Research 2008, 10:R67. 10.1186/bcr2128, 2575540, 18681955.
19. Al Tamimi DM, Bernard PS, Shawarby MA, Al-Amri AM, Hadi MA. Distribution of molecular breast cancer subtypes in Middle Eastern-Saudi Arabian women - A pilot study. Ultrastructural Pathology 2009, 33:141-150.
20. Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, Dabbs DJ. Prevalence, Morphologic Features and Proliferation Indices of Breast Carcinoma Molecular Classes Using Immunohistochemical Surrogate Markers. Int J clin Exp Pathol 2009, 444-455. 2655155, 19294003.
21. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2007, 31(1):18.
22. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Modern Pathology 2005, 18:1027-1033. 10.1038/modpathol.3800438, 15920544.
23. Foulkes WD, Stefansson IM, Chappui PO, Bégi LR, Goffin JR, Won N, Trude M, Akslen LA. Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer. Journal of the National Cancer Institute 2003, 95(19):1482-1485.
24. De Manzoni G, Verlato G, Tomezzoli A. Study of Ki 67 immunoreactivity as a prognostic indicator in patients with advanced gastric cancer. Jpn J Clin Oncol 1998, 28:534-537. 10.1093/jjco/28.9.534, 9793024.
25. Kleer CG, Giordano TJ, Braun T, Oberman HA. Pathologic, Immunohistochemical, and Molecular Features of Benign and Malignant Phyllodes Tumors of the Breast. Mod Pathol 2000, 14(3):185-190.
26. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. J Natl Cancer Inst 2009, 101:736-750. 10.1093/jnci/djp082, 2684553, 19436038.
27. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and HER2/neu-overexpressing phenotypes. Hum Pathol 2006, 37(9):1217-1226. 10.1016/j.humpath.2006.04.015, 16938528.
28. Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast cancer research and treatment 2007, 110(1):183-188. 10.1007/s10549-007-9694-5, 17674190.
29. Brennan DJ, Gallagher WM. Prognostic ability of a panel of immunohistochemistry markers - retailoring of an 'old solution'. Breast Cancer Res 2008, 10(1):102. 10.1186/bcr1854, 2374964, 18331621.
30. Guedj M. A synthetic review of the five molecular Sorlie's subtypes in breast cancer. , http://mickael.guedj.googlepages.com/mguedjCITReview01.pdf
31. Yu KD, Shen ZZ, Shao ZM. The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer. Breast Cancer Res Treat 2009, 118(3):661-663. 10.1007/s10549-009-0522-y, 19714461.
32. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11(16):5678-5685. 10.1158/1078-0432.CCR-04-2421, 16115903.
33. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009, 27(27):4515-4521. Epub 2009 Aug 24, 10.1200/JCO.2008.19.6873, 19704069.
34. Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumori 2008, 94(3):370-383.
35. Stendahl M, Rydén L, Nordenskjöld B, Jönsson PE, Landberg G, Jirström K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006, 12(15):4614-4618. 10.1158/1078-0432.CCR-06-0248, 16899609.
36. Albain K, Barlow W, O'Malley F, Siziopikou K, Yeh IT, Ravdin P, Lew D, Farrar W, Burton G, Ketchel S, , et al. for the breast cancer intergroup of North America Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, estrogen (ER) and/or progesterone (PR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 2004, 88:S20. (abstract 37), for the breast cancer intergroup of North America.
37. Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology 2009, 2:133-142.
38. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006, 17(5):818-826. 10.1093/annonc/mdl016, 16497822.
39. Adelaide J. Integrated profiling of basal and luminal breast cancers. Cancer Research 2007, 7:231.
40. Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M. Prognostic signifi cance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res 1996, 2(1):147-154.
41. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA, . International Breast Cancer Study Group Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors -- a surrogate marker?. Cancer 2003, 97(5):1321-1331. 10.1002/cncr.11188, 12599241, International Breast Cancer Study Group.
42. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96(10):1504-1513. 10.1038/sj.bjc.6603756, 2359936, 17453008.
43. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003, 63(19):6523-6531.
44. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G, . IMPACT Trialists Group Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99(2):167-170. 10.1093/jnci/djk020, 17228000, IMPACT Trialists Group.
45. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 1995, 104(1):42-49.
46. Bevilacqua P, Verderio P, Barbareschi M, Bonoldi E, Boracchi P, Dalla Palma P, Gasparini G. Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma. Breast Cancer Res Treat 1996, 37(2):123-133. 10.1007/BF01806494, 8750580.
47. Clahsen PC, Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, Broek L, Vijver MJ. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol 1999, 25(4):356-363. 10.1053/ejso.1999.0657, 10419704.
48. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population based study. Clin Cancer Res 2003, 9(3):923-930.
49. Goodson WH, Moore DH, Ljung BM, Chew K, Mayall B, Smith HS, Waldman FM. The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat 2000, 59(2):113-123. 10.1023/A:1006344010050, 10817346.
50. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS, . International Breast Cancer Study Group Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node negative breast cancer. J Natl Cancer Inst 2008, 100(3):207-212. 10.1093/jnci/djm289, 18230798, International Breast Cancer Study Group.
51. Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DAJ, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL. The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer. Journal of Clinical Oncology 2004, 22(1):86-96. 10.1200/JCO.2004.09.128, 14701769.
52. Barbiti A, Cosmi EV, Sidoni A, Collin P, Parpora MG, Ferri I, Luthy M, Lauro V, Bucciarelli E. Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer. Anticancer Res 1997, 17(1A):401-405.
53. Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, Lee CH, Li KB. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005, 18(3):374-381. 10.1038/modpathol.3800254, 15578079.
54. Kuroda H, Ishida F, Nakai M, Ohnisi K, Itoyama S. Basal cytokeratin expression in relation to biological factors in breast cancer. Hum Pathol 2008, 39(12):1744-1750. 10.1016/j.humpath.2008.06.007, 18755493.
55. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007, 16(1):104-107. 10.1016/j.breast.2006.09.003, 17097880.
56. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008, 26(26):4282-4288. 10.1200/JCO.2008.16.6231, 18779615.
57. Chen JQ, Russo J. ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta 2009, 1796(2):162-175.
58. Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 2008, 61:553-60. 10.1136/jcp.2008.055475, 18326009.